HK1250639A1 - 抗微生物療法 - Google Patents

抗微生物療法

Info

Publication number
HK1250639A1
HK1250639A1 HK18110063.1A HK18110063A HK1250639A1 HK 1250639 A1 HK1250639 A1 HK 1250639A1 HK 18110063 A HK18110063 A HK 18110063A HK 1250639 A1 HK1250639 A1 HK 1250639A1
Authority
HK
Hong Kong
Prior art keywords
antimicrobial therapy
antimicrobial
therapy
Prior art date
Application number
HK18110063.1A
Other languages
English (en)
Inventor
仲辻晃明
R‧L‧伽羅
Original Assignee
加利福尼亞大學董事會
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 加利福尼亞大學董事會 filed Critical 加利福尼亞大學董事會
Publication of HK1250639A1 publication Critical patent/HK1250639A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
HK18110063.1A 2015-05-05 2018-08-06 抗微生物療法 HK1250639A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562157248P 2015-05-05 2015-05-05
US201662300274P 2016-02-26 2016-02-26
PCT/US2016/031067 WO2016179440A2 (en) 2015-05-05 2016-05-05 Antimicrobial therapy

Publications (1)

Publication Number Publication Date
HK1250639A1 true HK1250639A1 (zh) 2019-01-11

Family

ID=57218441

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18110063.1A HK1250639A1 (zh) 2015-05-05 2018-08-06 抗微生物療法

Country Status (11)

Country Link
US (3) US20180289751A1 (zh)
EP (1) EP3291824A4 (zh)
JP (3) JP6981878B2 (zh)
KR (2) KR102624665B1 (zh)
CN (2) CN107735098B (zh)
AU (2) AU2016256882B2 (zh)
BR (1) BR112017023707B1 (zh)
CA (1) CA2984890C (zh)
HK (1) HK1250639A1 (zh)
MX (1) MX2017014020A (zh)
WO (1) WO2016179440A2 (zh)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102624665B1 (ko) * 2015-05-05 2024-01-12 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 항균 요법
CN105796624A (zh) * 2016-05-11 2016-07-27 西安膳方医药科技有限公司 一种改善生物体表健康的方法
WO2019030290A1 (en) * 2017-08-08 2019-02-14 Universite De Versailles-St Quentin En Yvelines PHARMACEUTICAL COMPOSITION AND METHODS FOR THE PREVENTION OF STAPHYLOCOCCUS AUREUS USING BACTERIAL ARTIFICIAL COLONIZATION
RU2699540C2 (ru) * 2017-08-17 2019-09-06 Павел Павлович Несмиянов Композиция, содержащая пробиотические бактерии или их компоненты, и способ ее применения в лечении иммунных заболеваний кожи
AU2019203692A1 (en) * 2018-08-30 2020-03-19 Johnson & Johnson Consumer Inc. Topical composition containing glycerin and yeast extract
MX2021003006A (es) 2018-09-13 2021-05-27 Univ California Bacterioterapia contra proprionibacterium acnes para el tratamiento de acne.
JP2022513599A (ja) * 2018-11-16 2022-02-09 アジトラ インコーポレーテッド Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ細菌の栄養要求性株
US20220062354A1 (en) 2018-12-21 2022-03-03 Matrisys Bioscience, Inc. Topical formulations for the delivery of microbially derived materials
WO2020150329A1 (en) * 2019-01-15 2020-07-23 Microbiome Labs, Llc Spore-based probiotic composition for modulation of dermal and sub-dermal properties
EP3922264A4 (en) * 2019-02-04 2024-01-10 Riken PHARMACEUTICAL COMPOSITION FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF SKIN DISEASES
US20220125860A1 (en) * 2019-02-05 2022-04-28 Elanco Us Inc. Probiotic compositions comprising lactobacillus reuteri strains and methods of use
CZ308231B6 (cs) 2019-02-11 2020-03-11 BiomCare s.r.o. Kombinované několikastupňové mikrobiální přípravky a způsob jejich aplikace
EP3705131A1 (en) * 2019-03-04 2020-09-09 University College Cork-National University of Ireland, Cork Lantibiotics and lantibiotic-producing bacteria
EP3934615A4 (en) * 2019-03-08 2023-01-25 The Regents Of The University Of California COMPOSITIONS AND METHODS FOR TREATMENT OF ACNE
JP2021001133A (ja) * 2019-06-21 2021-01-07 ポーラ化成工業株式会社 スタフィロコッカス・ホミニス（Ｓｔａｐｈｙｌｏｃｏｃｃｕｓ ｈｏｍｉｎｉｓ）を有効成分とする肌状態改善剤
DE102019007505A1 (de) * 2019-10-28 2021-04-29 Beiersdorf Ag Zusammensetzung mit probiotischen Bakterien und Licochalcon A
DE102019007507A1 (de) * 2019-10-28 2021-04-29 Beiersdorf Ag Zusammensetzung mit probiotischen Bakterien und Protektor-Stämmen
WO2021154954A1 (en) * 2020-01-29 2021-08-05 Etheim Biotics, Llc Compositions and methods for treating biofilms, infections and periodontitis
KR20220133262A (ko) * 2020-01-29 2022-10-04 더 잭슨 래보라토리 박테리아 혼합물
US20240058395A1 (en) * 2021-01-26 2024-02-22 The Regents Of The University Of California Antimicrobial therapy
EP4082545A1 (en) * 2021-04-27 2022-11-02 Diotheris Combination product and methods for preventing the emergence of antibiotic-resistant bacteria under antibiotic treatment
CN113730648B (zh) * 2021-09-06 2022-11-01 温州瑞司特生物科技有限公司 结合表皮葡萄球菌的水凝胶及其在治疗创面中的应用
CZ309480B6 (cs) * 2021-09-30 2023-02-15 BiomServ s.r.o Přípravky na ochranu mikrobiomu kůže a sliznic proti patogenním mikrobům a virům
EP4429683A1 (en) * 2021-11-11 2024-09-18 Concerto Biosciences, Inc. Microbial compositions for the treatment of skin diseases
WO2023119287A1 (en) * 2021-12-22 2023-06-29 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Institute) Nomadic bacteria and uses thereof
WO2023223993A1 (ja) * 2022-05-16 2023-11-23 マルホ株式会社 白癬治療用組成物
CN117343856A (zh) * 2022-06-28 2024-01-05 上海菌济健康科技有限公司 具有促进毛发生长的人体共生菌及其应用
EP4311537A1 (en) * 2022-07-26 2024-01-31 Beiersdorf AG Novel skin care composition for treating atopic dermatitis
CN116333923A (zh) * 2023-02-21 2023-06-27 上海市第一人民医院 一种人葡萄球菌SHoFu616菌株、其筛选方法和用于制备预防和治疗特应性皮炎药物的应用
CN116270368A (zh) * 2023-05-15 2023-06-23 天津悟空美容科技有限责任公司 一种抗痤疮化妆品及制备方法
CN118126876B (zh) * 2024-02-05 2024-10-11 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一株人型葡萄球菌及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925556A (en) * 1996-10-02 1999-07-20 Agency Of Industrial Science And Technology Method of degrading polylactic acid resin using staphylococcus hominis and staphylococcus epidermidis
US8207319B2 (en) * 2006-03-31 2012-06-26 Canon Kabushiki Kaisha Probe, probe set, probe-immobilized carrier, and genetic testing method
JP5161872B2 (ja) * 2006-05-12 2013-03-13 ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア 細菌感染に対する抗微生物療法
US20080026999A1 (en) * 2006-07-28 2008-01-31 Van Der Donk Wilfred A Two-component bacillus lantibiotic and methods for producing and using the same
US20100166708A1 (en) * 2007-02-20 2010-07-01 The Regents Of The University Of California Antimicrobial and anti-inflammatory therapies and compositions
US20090041727A1 (en) * 2007-08-08 2009-02-12 Conjugon, Inc. Compositions and Methods for Microbe Storage and Delivery
WO2011125015A2 (en) * 2010-04-05 2011-10-13 Bar-Ilan University Protease-activatable pore-forming polypeptides
US20130331384A1 (en) * 2011-02-15 2013-12-12 The Regents Of The University Of California Firmocidin, an antimicrobial molecule produced by staphylococcus epidermidis
EP3035802B1 (en) * 2013-08-19 2021-07-07 Syngulon SA Controlled growth of microorganisms
KR102624665B1 (ko) * 2015-05-05 2024-01-12 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 항균 요법

Also Published As

Publication number Publication date
CN115715781A (zh) 2023-02-28
CA2984890A1 (en) 2016-11-10
AU2016256882A1 (en) 2017-11-23
CA2984890C (en) 2023-04-11
KR20220101014A (ko) 2022-07-18
BR112017023707A2 (pt) 2018-07-31
JP2018515488A (ja) 2018-06-14
US10980848B2 (en) 2021-04-20
US20180289751A1 (en) 2018-10-11
JP7348255B2 (ja) 2023-09-20
KR102419616B1 (ko) 2022-07-12
CN107735098A (zh) 2018-02-23
EP3291824A2 (en) 2018-03-14
WO2016179440A3 (en) 2017-02-09
EP3291824A4 (en) 2019-01-23
MX2017014020A (es) 2018-08-14
AU2022203288A1 (en) 2022-06-09
US20200246397A1 (en) 2020-08-06
JP2023175748A (ja) 2023-12-12
CN107735098B (zh) 2022-07-29
KR20180002710A (ko) 2018-01-08
WO2016179440A2 (en) 2016-11-10
JP2022028833A (ja) 2022-02-16
US20210228652A1 (en) 2021-07-29
JP6981878B2 (ja) 2021-12-17
BR112017023707B1 (pt) 2022-03-29
AU2016256882B2 (en) 2022-06-02
KR102624665B1 (ko) 2024-01-12

Similar Documents

Publication Publication Date Title
HK1250639A1 (zh) 抗微生物療法
IL263521A (en) Combination therapy
IL257976A (en) Combined treatment
GB201516442D0 (en) Combination therapy
GB201512365D0 (en) Novel therapy
IL265406B (en) combined treatment
HK1255110A1 (zh) 組合療法
GB201502137D0 (en) Treatment
GB201609597D0 (en) Therapy
GB201604318D0 (en) Combination therapy
GB201508841D0 (en) Treatment
GB201604316D0 (en) Combination therapy
IL265340A (en) Combination therapy
GB201505382D0 (en) Novel therapy
GB201609735D0 (en) Combination therapy
GB201603653D0 (en) Combination Therapy
GB201516068D0 (en) Novel therapy
GB201503008D0 (en) Treatment
GB201618477D0 (en) Therapy
GB201615923D0 (en) Macrophage-based therapy
GB201613179D0 (en) Combination therapy
GB201609721D0 (en) Cobination therapy
GB201609322D0 (en) Therapy
GB201609312D0 (en) Therapy
GB201609766D0 (en) Combination therapy